Related Experiment Video
Updated: Apr 5, 2026
07:39
Co-culture of Glutamatergic Neurons and Pediatric High-Grade Glioma Cells Into Microfluidic Devices to Assess Electrical Interactions
Published on: November 17, 2021
4.1K
Low Grade Gliomas in Children.
Alan Chalil1, Vijay Ramaswamy2
1Arthur and Sonia Labatt Brain Tumor Research Centre, Hospital for Sick Children, Toronto, ON, Canada.
Journal of Child Neurology
|August 20, 2015
Summary
Pediatric low-grade gliomas are the most common nervous system tumors. Recent genomic advances are revolutionizing their treatment and driving new clinical trials for targeted therapies.
Area of Science:
- Neuro-oncology
- Pediatric oncology
- Genomics
Background:
- Gliomas are common nervous system tumors with varied prognoses based on grade.
- Morphological classification traditionally dictates risk stratification and treatment.
- Pediatric low-grade gliomas (PLGGs) have seen significant biological insights in the last decade.
Purpose of the Study:
- To review the current management of pediatric low-grade gliomas.
- To summarize key biological advances in PLGGs over the past 10 years.
- To highlight how these advances are informing future clinical trials.
Main Methods:
- Review of current literature on pediatric low-grade gliomas.
- Analysis of recent genomic and next-generation sequencing studies.
- Synthesis of biological findings and their impact on treatment paradigms.
Main Results:
- Morphological classification is the current standard for glioma risk stratification.
- Integrated genomics and next-generation sequencing have greatly expanded understanding of PLGG biology.
- Targeted therapies based on biological insights are emerging for PLGGs.
Conclusions:
- Advances in PLGG biology are transforming treatment strategies.
- Future clinical trials will increasingly focus on targeted therapies for PLGGs.
- A deeper understanding of PLGGs biology is crucial for improving patient outcomes.
